Oxford Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Oxford Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-491,000	Closed	-$10.7M	–	1838
2017 Q2	$10.7M	Buy	491,000 +461,774	+1,580%	+$8.38M	0.21%	63
2017 Q1	$410K	Buy	+29,226	New	+$479K	0.01%	1110
2016 Q2	–	Sell	-150,550	Closed	-$2.3M	–	945
2016 Q1	$2.3M	Sell	150,550 -126,755	-46%	-$1.99M	0.07%	337
2015 Q4	$5.68M	Buy	+277,305	New	+$5.27M	0.13%	155

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Oxford Asset Management's AMRI Position: Q3 2017 in Review

Oxford Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 491,000 shares — an estimated $10.7M sold.

Oxford Asset Management first reported a position in AMRI in Q4 2015 and held it in 4 quarters. The position peaked at $10.7M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Oxford Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Oxford Asset Management sold 491,000 Albany Molecular Research Inc shares in Q3 2017, an estimated $10.7M.
Oxford Asset Management first reported a position in Albany Molecular Research Inc in Q4 2015 and held it in 4 quarters.
Oxford Asset Management's Albany Molecular Research Inc position peaked at $10.7M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Oxford Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.